{"slug":"aod-9604","seoKey":"aod9604","displayName":"AOD-9604","codes":["AOD-9604","LAT-8881","hGH 176-191"],"synonyms":["AOD9604","AOD 9604","LAT8881","Tyr-hGH 177-191","hGH fragment 176-191","growth hormone fragment 176-191","Frag 176-191","Anti-Obesity Drug 9604","sh-Oligopeptide-74"],"legalClass":"research_chemical","identifiers":{"cas":"221231-10-3","pubchemCid":71300630,"unii":"7UP768IP4M","inchikey":"GVIYUKXRXPXMQM-BPXGDYAESA-N","wikidataQid":"Q72443552","formula":"C78H123N23O23S2","molecularWeight":1815.1,"sequence":"YLRIVQCRSVEGSCGF"},"approvals":[{"market":"US","status":"not_approved","note":"Not approved: no approved medicinal product, no component of one, and no agency response to any food-additive notification. A search of the agency's inventory of generally-recognised-as-safe notices returned no records on 2026-09-10, so no notice number exists. What does exist is a self-affirmed, expressly conditional determination made in 2012 by a private expert panel commissioned by the sponsor, covering oral use as a food ingredient only; it is not an authorisation, a clearance or a quality mark, and it says nothing about the injectable form. The substance is listed under bulk drug substances nominated but withdrawn for compounding, with the agency citing possible immunogenicity for certain routes of administration, complexities around peptide-related impurities and characterisation, no or only limited safety information, and serious adverse events of unclear causality. A warning letter issued on 2022-01-26 to a compounder covered a compounded injectable preparation over a lack of sterility assurance.","source":"https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks"},{"market":"EU","status":"not_approved","note":"Not approved: no centralised authorisation, no assessment report and no withdrawn application. The full-text and medicine searches returned no entry for the substance on 2026-09-10. A European novel-food application announced as an intention in 2012 is not traceable; a determination made in the United States has no legal effect here in any case.","source":"https://www.ema.europa.eu/en/medicines?search_api_fulltext=AOD-9604"},{"market":"DE","status":"not_approved","note":"Not approved: neither a centralised EU authorisation nor a national one exists, so every injectable preparation is an unauthorised medicinal product. The substance is at the same time named in the annex to the anti-doping act, in the section on growth hormone analogues and fragments, and under both of its common designations. The criminal and administrative offences of that act therefore apply to manufacture, trade, acquisition, possession in more than a small quantity and use in organised sport.","source":"https://www.gesetze-im-internet.de/antidopg/anlage.html"},{"market":"UK","status":"not_approved","note":"Not approved: the regulator's product index returned no entry on 2026-09-10. Unlicensed peptide preparations fall under the general rules for unauthorised medicines in the Human Medicines Regulations 2012.","source":"https://products.mhra.gov.uk/search/?search=AOD-9604"},{"market":"AU","status":"scheduled","date":"2026-05-28","note":"The strictest documented classification of any market: named in the Poisons Standard in Schedule 4 (prescription only) and additionally in Appendix D, clause 5, which makes possession without authority unlawful. The index of the instrument confirms both entries under the substance name and its registry number. No registered finished product exists, which leaves the notable combination of a prescription requirement for a substance no prescriber can obtain as an authorised medicine, plus a possession ban.","source":"https://www.legislation.gov.au/F2026L00633/asmade"},{"market":"CA","status":"not_approved","note":"Not approved: the active-ingredient query of the drug product database returned an empty result on 2026-09-10. A control query for a comparable substance returned matches in the same call, so the negative finding is sound.","source":"https://health-products.canada.ca/api/drug/activeingredient/?ingredientname=AOD"},{"market":"CH","status":"not_approved","note":"Not approved: the substance appears in none of the published lists of authorised human medicines, checked on 2026-09-10. A joint enforcement action by the medicines, customs and sport integrity authorities in June 2026 held back 23 of 46 inspected peptide consignments, 21 of them categorised as doping; the notice does not name this substance but covers exactly this product category.","source":"https://www.swissmedicinfo.ch/"}],"devStage":"discontinued","strongestEvidence":"rct_phase2","wada":{"status":"prohibited","section":"S2.2.3","listYear":2026,"source":"https://www.wada-ama.org/en/prohibited-list"},"trials":[{"nct":"NCT03865953","name":"Oral LAT-8881 in neuropathic pain (primary endpoint missed)","phase":"Phase 2","n":53,"status":"COMPLETED"},{"nct":"NCT04153409","name":"Oral LAT-8881 in acute migraine, proof of concept (primary endpoint missed at every timepoint)","phase":"Phase 2","n":21,"status":"COMPLETED"},{"nct":"NCT05298306","name":"Intravenous LAT-8881 in lumbar radicular pain, two-part proof of concept (primary endpoint missed; only published human pharmacokinetics)","phase":"Phase 1","n":26,"status":"COMPLETED"}],"sameAs":["https://www.wikidata.org/wiki/Q72443552","https://pubchem.ncbi.nlm.nih.gov/compound/71300630"],"lastVerified":"2026-09-10","version":"1.0","published":true,"locale":"en","title":"AOD-9604: what the trials show, status and safety","summary":"AOD-9604 is a lab-made piece of human growth hormone, designed to burn fat without acting like the hormone. Nine trials tested it in people. The largest, in 502 adults with obesity, missed its weight target, and the company ended the project in 2007. Three later pain trials failed too. No country has approved it, and the anti-doping list names it.","updated":"2026-09-10","url":"https://mypep.app/peptides/aod-9604"}